Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 153,400 shares, an increase of 95.4% from the March 31st total of 78,500 shares. Based on an average daily volume of 648,100 shares, the days-to-cover ratio is presently 0.2 days.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Avalo Therapeutics stock. Acadian Asset Management LLC bought a new stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 283,306 shares of the company’s stock, valued at approximately $34,000. Acadian Asset Management LLC owned 1.40% of Avalo Therapeutics at the end of the most recent quarter. 87.06% of the stock is currently owned by institutional investors and hedge funds.
Avalo Therapeutics Stock Performance
NASDAQ AVTX traded up $1.00 on Friday, reaching $15.98. The stock had a trading volume of 73,802 shares, compared to its average volume of 537,467. Avalo Therapeutics has a 12-month low of $3.95 and a 12-month high of $1,130.40. The business’s 50-day moving average price is $9.19 and its 200 day moving average price is $13.46. The stock has a market cap of $16.46 million, a P/E ratio of -0.03 and a beta of 1.15.
Analysts Set New Price Targets
View Our Latest Report on Avalo Therapeutics
Avalo Therapeutics Company Profile
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein.
Featured Stories
- Five stocks we like better than Avalo Therapeutics
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- 3 Stocks Leading the U.S. Agriculture Comeback
- How to Use the MarketBeat Excel Dividend Calculator
- How to Use Put Debit Spreads to Profit From Falling Stocks
- What is the S&P/TSX Index?
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.